Loading...
•
Jun 30
Abbott Q2 2025 Earnings Report
Abbott reported solid Q2 2025 results with strong EPS growth and robust medical devices performance.
Key Takeaways
Abbott delivered strong Q2 2025 results, posting solid revenue growth, double-digit EPS growth, and significant momentum in its medical devices segment, driven by products like FreeStyle Libre and structural heart devices.
Revenue grew 7.4% YoY to $11.14B
GAAP EPS was $1.01; adjusted EPS $1.26
Net income increased 36.7% YoY to $1.78B
Medical Devices sales rose 13.4%, led by Diabetes Care and heart-related products
Abbott
Abbott
Abbott Revenue by Segment
Abbott Revenue by Geographic Location
Revenue by Segment
Nutrition Revenue
CapyFin.comDiagnostics Revenue
CapyFin.comEstablished Pharma Revenue
CapyFin.comMedical Devices Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Abbott expects strong growth to continue in 2025 with solid EPS and margin expansion.
Positive Outlook
- Full-year 2025 organic sales growth projected at 7.5%-8.0% excluding COVID-19 tests
- Full-year adjusted EPS guidance of $5.10 to $5.20
- Q3 2025 adjusted EPS projected at $1.28 to $1.32
- Continued margin expansion expected
- Strong pipeline with recent product approvals and clinical trial progress
Challenges Ahead
- COVID-19 testing-related sales continue to decline
- Volume-based procurement programs in China affecting diagnostics growth
- Foreign exchange expected to be a headwind
- Nutrition business growth remains modest
- Regulatory and integration costs continue to impact expenses
Revenue & Expenses
Visualization of income flow from segment revenue to net income